Pharmaron and MSD agree deal to acquire MSD’s UK Hoddesdon site
MSD to continue to remain on site and lease the main office buildings as part of a shared site agreement
Beijing, September 26, 2016 Pharmaron has entered into a non-binding Heads of Terms (HoTs) with Merck Sharpe & Dohme Limited (MSD) for the sale of the Hoddesdon UK site which includes MSD’s process development and research facility. The parties hope to complete the deal in Q1 2017.
Pharmaron sees this as a unique opportunity to acquire state-of-the-art Good Manufacturing Practice (GMP) standard facilities for the development of Active Pharmaceutical Ingredients (API) and formulation development in Europe to complement Pharmaron’s existing world class chemistry and integrated drug discovery and development services globally. Under the deal, MSD will remain on site on and lease-back the main office buildings.
Louise Houson, Managing Director, MSD UK and Ireland commented: “We are very pleased to be progressing this deal with Pharmaron. This deal will secure the future of the site while meeting the changing business needs of MSD and its employees for the foreseeable future. It also ensures MSD’s scientific legacy in Hoddesdon continues, with the potential to create local opportunities for our scientific staff in their areas of expertise.”
Boliang Lou, Chairman and CEO of Pharmaron commented that: “This is an exciting opportunity to have an industry-leading R&D site join the Pharmaron group, which once again demonstrates our commitment to our mission to become a world leader in small molecule drug R&D services. It allows us to develop our global capabilities in process chemistry and manufacturing services area, strengthening our capabilities in fully integrated R&D services. Together with the recent addition of GMP radiochemistry and GCP/GLP metabolism platforms through acquisition of Quotient Bioresearch in the U.K., this deal further consolidates our strategic position in Europe to better serve our partners globally, particularly in Europe.”
Commercial details on the transaction are not being disclosed.
About Pharmaron
Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism to chemical & pharmaceutical development. With about 4,000 employees and operations in China, the U.S. and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, please visit: www.www.pharmaron.com
About MSD
For 125 years, MSD has been a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., Kenilworth, NJ., USA. Through our prescription medicines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information, visit www.msd-uk.com.
For more information, please contact:
Pharmaron:
Ashok Tehim, Sr. VP, Strategy, Tel: +1 201 312 5754, ashok.tehim@pharmaron.com
Ellen Cabral, Director, Global Marketing, Tel: +1 617 901 2216, ellen.cabral@pharmaron.com
MSD: Meral Nugent, Tel: 01992 452358, Mob: 07884 232042, meral.nugent@merck.com
康龙化成与默沙东就收购默沙东英国霍兹登园区达成一致协议
协议同时同意默沙东公司继续租用部分场地用于日常办公
2016年9月26日，北京_康龙化成与默沙东（MSD）就购买默沙东英国霍兹登园区签订非限制性条款，此项收购涉及默沙东英国霍兹登的化学工艺研发及制剂等各项实验设施。双方希望此项交易能于2017年一季度完成。
康龙化成看准这一获取世界一流GMP设施的特殊机会，以推动其在原料药及制剂研发服务领域的发展，进一步夯实其在化学合成及一体化药物研发服务领域的全球领先地位。根据协议，默沙东将继续租用部分场地用于日常办公。
默沙东英国及爱尔兰区总经理路易丝.赫森女士表示，“我们非常高兴与康龙化成在此项协议中取得进展。它不仅使该园区得以完整保留，默沙东在霍兹登的科研遗产得以延续，而且满足了默沙东业务发展需求，同时为我们的科研人员提供了其专业领域内就近工作的机会。”
康龙化成董事长兼首席执行官楼柏良博士表示，“这是一件振奋人心的事情，行业领先的研发基地加入康龙化成大家庭，再次证明了康龙化成致力于成为小分子药物研发服务领域全球引领者的决心。它将加速我们在全球范围内的工艺化学及生产领域的研发服务能力建设，进一步增强康龙化成一体化研发服务水平。连同近期通过收购英国的Quotient Bioresearch公司搭建的GMP 放射化学和GCP/GLP 药物代谢平台，这笔交易将进一步巩固我们在欧洲的战略地位，为我们的全球客户，尤其是欧洲客户，提供更好的服务。”
双方并没有对交易细节做更多的披露。
关于康龙化成
康龙化成新药技术有限公司（非上市企业），成立于2003年，是国际领先的生命科学研发服务企业。公司宗旨为“以最高水平的研发服务，帮助伙伴们成功开发新药，降低新药研发成本，提高新药研发效率”。经过多年发展，康龙化成打造了全方位的临床前药物研发一体化平台，贯穿合成与药物化学、生物、药物代谢及药代动力学、药理、药物安全评价、放射标记代谢、工艺研发、GMP生产及制剂研发服务等各个领域，提供包括苗头化合物探索与靶标验证、先导化合物优化、临床前候选药物筛选、新药临床研究申请和新药申报等一体化研发服务。康龙化成在中国、美国、英国均有运营实体，拥有4000多名员工，一流的人才队伍，高质量的研发服务，获得了业界的广泛认可，与北美、欧洲、日本和中国的各医药公司/机构保持着长期、稳固的合作关系。详情请访问公司网站：www.www.pharmaron.com
关于默沙东
125年来，默沙东公司一直致力于成为全球医疗领域的领先者，致力于让世界健康。凭借处方药、生物制品与动物保健品，我们与全球的客户共同合作，为全球140多个国家提供创新的医疗解决方案。通过广泛的政策、项目与合作计划，我们不断履行承诺，提高医疗服务的可及性。详情请访问公司网站：www.msd-uk.com
详情请联系：
康龙化成：
Ashok Tehim博士，高级副总裁，企业战略，Tel: +1 201 312 5754, ashok.tehim@pharmaron.com
Ellen Cabral女士， 全球市场营销总监，Tel: +1 617 901 2216, ellen.cabral@pharmaron.com
默沙东：Meral Nugent女士, Tel: 01992 452358, Mob: 07884 232042, meral.nugent@merck.com